

5-Fluorouracil + Mitomicina C

5-Fluorouracil: 1,000 mg/m²/dia IV por infusão contínua D1–4 e D29–32 concomitante a radioterapia

Mitomicina C: 15 mg/m² IV no D1

Ref. (1)

5-Fluorouracil + Mitomicina C

5-Fluorouracil: 750 mg/m²/dia IV infusão contínua D1-5 e D29–33, concomitante a radioterapia

Mitomicina C: 15 mg/m² IV no D1

Ref. (2)

5-Fluorouracil + Cisplatina

5-Fluorouracil: 1,000 mg/m²/dia IV infusão contínua nos D1 a 5

Cisplatina: 75 mg/m² IV D2

Ref. (3)

Capecitabina + Mitomicina C

Capecitabina: 825mg/m² VO BID durante os dias da radioterapia

Mitomicina C: 12mg/m² IV D1

Ref. (4)

1. Nigro ND, *et al.* Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. *Cancer* 1983;51:1826–1829.
2. Bartelink H, *et al.* Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of

Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040–2049.

3. Hung A, *et al.* Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. *Cancer* 2003; 97:1195–1202.
4. Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D. Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer. *Int J Radiat Oncol Biol Phys.* 2008 May 7.